Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: The ECCO-EpiCom cohort

Inflammatory Bowel Diseases

Volumn 20, Issue 1, 2014, Pages 36-46

  Burisch, Johan ^a   Pedersen, Natalia ^a   Cukovic Cavka, Silvja ^b   Turk, Niksa ^b   Kaimakliotis, Ioannis ^c   Duricova, Dana ^d   Shonová, Olga ^e   Vind, Ida ^f   Avnstrøm, Søren ^f   Thorsgaard, Niels ^g   Krabbe, Susanne ^h   Andersen, Vibeke ^h,i,j   Jens, Frederik Dahlerup ^k   Kjeldsen, Jens ^l   Salupere, Riina ^m   Olsen, Jóngerd ⁿ   Nielsen, Kári Rubek ⁿ   Manninen, Pia ^o   Collin, Pekka ^o   Katsanos, Konstantinnos H ^p   Tsianos, Epameinondas V ^p   Ladefoged, Karin ^q   Lakatos, Laszlo ^r   Bailey, Yvonne ^s   O'Morain, Colm ^s   Schwartz, Doron ^t   Odes, Selwyn ^t   Martinato, Matteo ^u,v   Lombardini, Silvia ^v,w   Jonaitis, Laimas ^x   Kupcinskas, Limas ^y   Turcan, Svetlana ^y   Barros, Louisa ^z   Magro, Fernando ^aa,ab,ac   Lazar, Daniela ^ad   Goldis, Adrian ^ad   Nikulina, Inna ^ae   Belousova, Elena ^ae   Fernandez, Alberto ^af   Hernandez, Vicent ^ag   Almer, Sven ^ah,ai   Zhulina, Yaroslava ^aj   Halfvarson, Jonas ^aj,ak   Tsai, Her Hsin ^al   Sebastian, Shaji ^al   Lakatos, Peter Laszlo ^am   Langholz, Ebbe ^a   Munkholm, Pia ^a   more..

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b KBC Zagreb   (Croatia)

^c Private Practice   (Cyprus)

^d CHARLES UNIVERSITY   (Czech Republic)

^e Ceske Budejovice Hospital   (Czech Republic)

^f AMAGER HOSPITAL   (Denmark)

^g HERNING HOSPITAL   (Denmark)

^h VIBORG HOSPITAL   (Denmark)

ⁱ Hospital of Southern Jutland   (Denmark)

^j UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^k AARHUS UNIVERSITY HOSPITAL   (Denmark)

^l ODENSE UNIVERSITY HOSPITAL   (Denmark)

^m TARTU UNIVERSITY HOSPITAL   (Estonia)

ⁿ National Hospital of the Faroe Islands   (Faroe Islands)

^o TAMPERE UNIVERSITY HOSPITAL   (Finland)

^p UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^q Dronning Ingrids Hospital   (Greenland)

^r Csolnoky F Province Hospital   (Hungary)

^s ADELAIDE AND MEATH HOSPITAL   (Ireland)

^t BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^u UNIVERSITY OF PADOVA   (Italy)

^v EpiCom Northern Italy Centre Based in Crema and Cremona   (Italy)

^w S MARIA NUOVA HOSPITAL   (Italy)

^x LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^y STATE UNIVERSITY OF MEDICINE AND PHARMACY NICOLAE TESTEMITANU   (Moldova)

^z Hospital de Vale de Sousa   (Portugal)

^aa HOSPITAL DE SÃO JOÃO   (Portugal)

^ab Institute of Pharmacology and Therapeutics Oporto Medical School   (Portugal)

^ac UNIVERSITY OF PORTO   (Portugal)

^ad VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^ae M F VLADIMIRSKY MOSCOW REGIONAL RESEARCH CLINICAL INSTITUTE   (Russian Federation)

^af HOSPITAL POVISA   (Spain)

^ag UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^ah U of Gastroenterol and Hepatology   (Sweden)

^ai Local Health Care Services in Central Östergötland   (Sweden)

^aj ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^ak ÖREBRO UNIVERSITY   (Sweden)

^al HULL ROYAL INFIRMARY   (United Kingdom)

^am SEMMELWEIS UNIVERSITY   (Hungary)

more..

Author keywords

Crohn's disease; Epidemiology; Outcomes research; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CANCER DIAGNOSIS; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; EASTERN EUROPE; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEMICOLECTOMY; HUMAN; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION BASED CASE CONTROL STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR; TIME TO TREATMENT; TOTAL COLON RESECTION; TREATMENT DURATION; ULCERATIVE COLITIS; VERY ELDERLY; WESTERN EUROPE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; DISEASE PROGRESSION; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; YOUNG ADULT;

EID: 84893671655     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000436277.13917.c4     Document Type: Article

References (47)

1. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
2. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39:690-697.
3. Wolters FL, Russel MG, Sijbrandij J, et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut. 2006;55:1124-1130.
4. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507-515.
5. Wolters FL, Russel MG, Sijbrandij J, et al. Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut. 2006;55:510-518.
6. Höie O, Schouten LJ, Wolters FL, et al. Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis. Gut. 2007;56:497-503.
7. Burisch J, Pedersen N, Cukovic-Cavka S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. [published online ahead of print April 20, 2013]. doi: 10.1136/gutjnl-2013-304636.
8. Munkholm P. Crohn's disease-occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull. 1997;44:287-302.
9. Langholz E. Ulcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis. Dan Med Bull. 1999;46:400-415.
10. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101:1274-1282.
11. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5-36.
12. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32.
13. Higgins PDR, Schwartz M, Mapili J, et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005;54:782-788.
14. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
15. Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis. 2006;12:304-310.
16. World Health Organisation. International Statistical Classification of Diseases and Related Health Problems 10th Revision. 2010. Available at: http:// apps.who.int/classifications/icd10/browse/2010/en. Accessed May 1, 2013.
17. Burisch J, Cukovic-Cavka S, Kaimakliotis I, et al. Construction and validation of a web-based epidemiological database for inflammatory bowel diseases in Europe An EpiCom study. J Crohns Colitis. 2011; 5:342-349.
18. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: current management. J Crohns Colitis. 2012;6:991-1030.
19. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28-62.
20. Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322-337.
21. Lennard-Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol. 1997;9:353-359.
22. Lakatos L, Kiss LS, David G, et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis. 2011;17:2558-2565.
23. Nguyen GC, Nugent Z, Shaw S, et al. Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology. 2011;141:90-97.
24. Solberg IC, Vatn MH, Høie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430-1438.
25. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431-440.
26. Targownik LE, Singh H, Nugent Z, et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107:1228-1235.
27. Ramadas AV, Gunesh S, Thomas GA, et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010;59: 1200-1206.
28. Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for the inflammatory bowel diseases has decreased over time: a systematic review and metaanalysis of population-based studies. Gastroenterology. 2013;145:996-1006.
29. Lakatos PL, Golovics PA, David G, et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol. 2012;107:579-588.
30. Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine versus conventional management of Crohn's disease: a randomized controlled trial. Gastroenterology. 2013;145:758-765.
31. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995;30:699-706.
32. Samuel S, Ingle SB, Dhillon S, et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis. 2013;19:1858-1866.
33. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012;107:1409-1422.
34. Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-a therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268-1276.
35. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population- based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007;13:481-489.
36. van der Valk ME, Mangen M-JJ, Leenders M, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFa therapy: results from the COIN study. Gut. [published online ahead of print November 7, 2012]. doi: 10.1136/gutjnl-2012-303376.
37. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194-1201.
38. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
39. Lakatos L, Lakatos PL. Management of inflammatory bowel diseases in Eastern Europe. Postgrad Med J. 2006;82:270-273.
40. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a populationbased cohort. Gastroenterology. 2010;139:1147-1155.
41. Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31:260-266.
42. Höie O, Wolters F, Riis L, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide populationbased cohort. Am J Gastroenterol. 2007;102:1692-1701.
43. Ford AC, Kane S V, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:617-629.
44. Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology. 2004;127:730-740.
45. Duricova D, Pedersen N, Elkjaer M, et al. 5-Aminosalicylic acid dependency in Crohn's disease: a Danish Crohn Colitis Database study. J Crohns Colitis. 2010;4:575-581.
46. Duricova D, Pedersen N, Lenicek M, et al. The clinical implication of drug dependency in children and adults with inflammatory bowel disease: a review. J Crohns Colitis. 2011;5:81-90.
47. Juillerat P, Pittet V, Mottet C, et al. Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohort. Scand J Gastroenterol. 2010;45:1449-1456.